Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Media Invite: Drug breakthrough for psoriasis sufferers

14.10.2005


An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.



A Global Press Briefing & Lunch will be held on Friday, 14 October from 11:30 – 13:00 in London. See details under "Notes for Edotors".

The European Infliximab for Psoriasis Efficacy and Safety Study (EXPRESS) was a placebo-controlled trial on 378 patients with moderate to severe psoriasis, to test the efficacy and safety of the drug. The findings, published in the 15 October issue of The Lancet, show that 80% of patients achieved at least a 75% improvement in symptoms after ten weeks treatment with the drug, as opposed to just 3% of those receiving a placebo.


Psoriasis is a chronic condition which results when skin cells over-produce and accumulate on the surface of the skin, producing red, scaly ‘plaques’ which may itch and bleed. It is thought to be genetic in origin and is a consequence of an abnormal inflammatory response in the skin. Around 2% of the population suffer from the disease, with about 30% of cases considered moderate to severe, but until now treatment options have been limited.

Infliximab blocks the activity of ‘tumour necrosis factor alpha’ (TNF-alpha), a protein involved in inflammation, and the vast majority of the trial subjects treated with the drug achieved clinically-significant levels of skin clearance. Nearly 60% experienced at least a 90% improvement in symptoms – or near-complete skin clearance – after ten weeks, versus 1% receiving the placebo, whilst 26% achieved complete skin clearance (versus 0% receiving the placebo). The improvements continued throughout the 50-week study.

Professor Christopher Griffiths, the University academic leading the trial from the Dermatology Centre at Hope Hospital, Salford, said: “These results indicate that Infliximab is a very effective therapy among the newer biological treatments for psoriasis. As a dermatologist, I am very encouraged by the data, which show that patients with moderate to severe psoriasis can rapidly achieve skin clearance and that these results can be maintained.”

Patients receiving Infliximab also experienced a good response in nail psoriasis, which is present in 20 – 50% of psoriasis patients and often thought of as a treatment-resistant disease. By week 24 of the trial, those receiving the drug were experiencing a 56% average decrease in this condition, and again this response was maintained throughout the trial.

“Physicians’ assessments of the patients’ conditions backed up our findings,” confirmed Professor Griffiths, “with 83% of those receiving the drug assessed as having minimal or cleared symptoms by week 10 of the trial as opposed to just 4% of those receiving the placebo.”

Jo Grady | alfa
Further information:
http://www.manchester.ac.uk/press/

More articles from Life Sciences:

nachricht Switch-in-a-cell electrifies life
18.12.2018 | Rice University

nachricht Plant biologists identify mechanism behind transition from insect to wind pollination
18.12.2018 | University of Toronto

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data storage using individual molecules

Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.

Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Physicists found a correlation between the structure and magnetic properties of ceramics

18.12.2018 | Physics and Astronomy

Unique insights into an exotic matter state

18.12.2018 | Physics and Astronomy

Physicists studied the influence of magnetic field on thin film structures

18.12.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>